Cite
HARVARD Citation
Goepfert, P. et al. (2021). Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet infectious diseases. 21 (9), pp. 1257-1270. [Online].